SCHEMBL8664696

SCHEMBL8664696

Nc1ncnc2[nH]c(=O)sc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LIMK1 P53667 10/20 0.39
CDC7 O00311 4/20 0.39
CDK5 Q00535 3/20 0.39
RET P07949 3/20 0.39
KDR P35968 3/20 0.39
AURKB Q96GD4 3/20 0.39
RPS6KA3 P51812 3/20 0.39
DAPK3 O43293 2/20 0.39
PRKD3 O94806 2/20 0.39
MAP4K4 O95819 2/20 0.39
CSNK1A1 P48729 2/20 0.39
CLK4 Q9HAZ1 2/20 0.39
PLK4 O00444 2/20 0.39
AURKA O14965 2/20 0.39
ROCK2 O75116 2/20 0.39
PIM1 P11309 2/20 0.39
PRKACA P17612 2/20 0.39
RPS6KB1 P23443 2/20 0.39
CDK2 P24941 2/20 0.39
MARK3 P27448 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8663522 0.76 ERAP1 (0.47) LIMK1CDC7CDK5RETKDR
SCHEMBL21895409 0.73 AURKA (0.42) AURKBAURKAPDE3BPDE3A
SCHEMBL22060804 0.69 RPS6KA3 (0.37) LIMK1RPS6KA3PDE3BPDE3A
SCHEMBL21895411 0.69 PDE3B (0.37) AURKAPDE3BPDE3AKDM4EALDH1A1
SCHEMBL21895447 0.69 RPS6KA3 (0.37) RPS6KA3TYRO3DYRK1B
SCHEMBL3816282 0.68 PDPK1 (0.43) CDC7CDK5RETDAPK3PRKD3
SCHEMBL338324 0.67 PDE3B (0.42) CDC7RPS6KA3PDE3BPDE3AKDM4E
SCHEMBL17904270 0.65 RPS6KA3 (0.37) RPS6KA3PDE3BPDE3AKDM4EALDH1A1
SCHEMBL338446 0.65 PDE3B (0.49) PDE3BPDE3A
SCHEMBL29585324 0.65 MEN1 (0.39) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12152051-B2 Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application Shanghai De Novo Pharmatech Co., Ltd. (CN) 2024-11-26 US disclosed
EP-3854799-B1 CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION SHANGHAI DE NOVO PHARMATECH CO LTD (CN) 2024-07-17 EP disclosed
EP-3854799-B1 CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION SHANGHAI DE NOVO PHARMATECH CO LTD (CN) 2024-07-17 EP disclosed
CN-110938104-B Cyclic dinucleotide analogue, pharmaceutical composition and application thereof 上海迪诺医药科技有限公司 2024-07-12 CN disclosed
EP-3854799-A1 CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION Shanghai de Novo Pharmatech Co., Ltd. (CN) 2021-07-28 EP disclosed
EP-3854799-A1 CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION Shanghai de Novo Pharmatech Co., Ltd. (CN) 2021-07-28 EP disclosed
CN-110938104-A Cyclic dinucleotide analogs, pharmaceutical compositions and uses thereof 上海迪诺医药科技有限公司 2020-03-31 CN disclosed
WO-2020057546-A1 CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION 上海迪诺医药科技有限公司 2020-03-26 WO disclosed
WO-2020057546-A1 CYCLIC DINUCLEOTIDE ANALOGUE, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATION 上海迪诺医药科技有限公司 2020-03-26 WO disclosed
EP-0636372-B1 Antiviral, antitumor, antimetastatic, immune system enhancing 7-thia-guanosine derivatives ICN PHARMACEUTICALS (US) 1998-12-02 EP disclosed
EP-0348446-B1 ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES UNIV BRIGHAM YOUNG (US) 1995-08-09 EP disclosed
EP-0636372-A1 Antiviral, antitumor, antimetastatic, immune system enhancing 7-thia-guanosine derivatives BRIGHAM YOUNG UNIVERSITY (US) 1995-02-01 EP disclosed
EP-0348446-A4 ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES 1991-09-25 EP disclosed
US-5041426-A Viricides, antitumor agents BRIGHAM YOUNG UNIVERSITY (US) 1991-08-20 US disclosed
EP-0348446-A1 ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES. UNIV BRIGHAM YOUNG (US) 1990-01-03 EP disclosed
US-4880784-A ANTITUMOR AGENTS BRIGHAM YOUNG UNIVERSITY (US) 1989-11-14 US disclosed
WO-1989005649-A1 ANTIVIRAL ANTITUMOR ANTIMETASTATIC IMMUNE SYSTEM ENHANCING NUCLEOSIDES AND NUCLEOTIDES BRIGHAM YOUNG UNIVERSITY (US) 1989-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12152051-B2 Cyclic dinucleotide analogue, pharmaceutical composition thereof, and application STING1, CGAS, IRF3 LIMK1 3885/4885CDC7 1259/4885CDK5 4042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.